Quidelortho's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Quidelortho's ROI in the second quarter of 2026?
Quidelortho Corp had a negative return on investment (ROI) of -19.31%, due to the net loss of $-1 billion, during the twelve months ending in the second quarter of 2026.

Within the Healthcare sector 306 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 28 2026 quarter, so far to 3407, from total ROI ranking in the first quarter of 2026 at 3939.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 28 2026) II. Quarter	(Mar 29 2026) I. Quarter	(Dec 28 2025) IV. Quarter	(Sep 28 2025) III. Quarter	(Jun 29 2025) II. Quarter
Y / Y Investment Change TTM	-0.63 %	-12.32 %	-11 %	-16.68 %	-19.34 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	7,335	4,666	4,803	4,907	5,237
Return On Investment (TTM)	-19.31 %	-24.69 %	-22.23 %	-22.48 %	-8.54 %
QDEL's Overall Ranking	# 3407	# 3939	# 3462	# 3104	# 3049
Seq. Investment Change TTM	10.7 %	-3.67 %	-2.96 %	-3.97 %	-2.32 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-1,048	-1,211	-1,132	-1,180	-466

QDEL Company Profile >> Back to QDEL Roi Comparisons >> See Annual QDEL Return On Investment

Return On Investment QDEL's Ranking
Within:	No.
Industry	# 5
Sector	# 307
Overall	# 3407

Return On Investment Statistics
High	Average	Low
73.44 %	5.51 %	-35.19 %
(Dec 31 2020)		(Dec 29 2024)

News about Quidelortho Corp Return on Investment ROI

Navigating Innovation Amid Financial Challenges QuidelOrtho’s VITROS Syphilis Assay Gains FDA Clearance,

August 29, 2024

SAN DIEGO QuidelOrtho Corporation (Nasdaq: QDEL) (QuidelOrtho) has recently achieved a significant regulatory milestone that could enhance its position in the healthcare diagnostics market. The company received U.S. Food and Drug Administration (FDA) 510(k) clearance for its VITROS Syphilis Assay. This approval allows the syphilis assay to be included in the diagnostic testing menu of its advanced VITROS platforms, specifically the VITROS 3600 Immunodiagnostic System, the VITROS 5600 Integrated System, and the VITROS XT 7600 Integrated System. The cleared VITROS Syphilis Assay is designed for the qualitative determination of total antibodies (IgG and IgM) against the Treponema pallidum (TP)-specific antigens in human serum and plasma. This automated testing system is crucial for diagnosing syphilis a persistent public health issue. The introduction of this assay will likely bolster QuidelOrtho’s standing in infectious disease testing, an area where the company has already shown significant expertise. Potential Market Impact The FDA approval is a crucial step forward and diversifies QuidelOrtho s testing portfolio, a necessity in the rapidly evolving diagnostics landscape. The automated nature of the VITROS Syphilis Assay is particularly relevant, offering laboratories a seamless integration into existing workflows, thus increasing efficiency and potentially reducing human error. Such advancements are expected to meet the growing demand for precise and timely diagnostic solutions.

Financial Statements
Quidelortho's II. Quarter Investments	$ 7,335 Millions	QDEL's Balance sheet
Quidelortho's II. Quarter Income	$ -93 Millions	Quarterly QDEL's Income Statement
QDEL's Income by Division		See QDEL's Income by Division

QDEL Annual Return On Investment	(Dec 28 2025) 2025	(Dec 29 2024) 2024	(Dec 31 2023) 2023	(Jan 01 2023) 2022	(Dec 31 2021) 2021
Total Investments in Millions	4,803	5,425	7,729	7,849	2,107
Y / Y Investment Growth	-11.46 %	-29.82 %	-1.52 %	272.54 %	37.33 %
Net Income in Millions	-1,132	-2,052	-10	549	704
Y / Y Net Income Growth	-	-	-	-22.08 %	-13.09 %
Annual Return On Investment	-23.56 %	-37.83 %	-0.13 %	6.99 %	33.43 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
In Vitro & In Vivo Diagnostic Substances Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
QDEL's Roi Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for QDEL's Competitors
Subscribers only: Roi for Quidelortho's Suppliers
Subscribers only: Return On Investment for QDEL's Customers

Other Ratios
QDEL's Roa	QDEL's Inventory Turnover Ratio	QDEL's Growth Rates	QDEL's Dividend Statistics
	QDEL's Profitability Ratios	QDEL's Asset Turnover Ratio	QDEL's Dividend Growth
QDEL's Roe	QDEL's Valuation Ratios	QDEL's Financial Strength Ratios	QDEL's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 28 2026, within Healthcare Sector

ROI

Date modified: 2026-09-26T07:41:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.